|
Predictive Effect of TGF-β and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients
RECRUITINGSponsored by Xie Kangjie
Actively Recruiting
SponsorXie Kangjie
Started2024-05-20
Est. completion2025-12-30
Eligibility
Age65 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06426953
Summary
To investigate the relationship between POD, TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) in diabetic patients
Eligibility
Age: 65 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Age ≥65 years 2. History of diabetes ≥2 years and Glycated hemoglobin ≥6.5% or no history of diabetes and normal blood glucose 3. The ASA rating is Class I to III 4. The elderly patients of limited thoracic and abdominal tumor surgery Exclusion Criteria: 1. Refused to participate 2. Previous history of schizophrenia, epilepsy, Parkinson's disease 3. History of alcohol abuse or drug dependence 4. Patients with ASA grade IV and above 5. Severe visual or hearing impairment, can not cooperate with the completion of cognitive function tests 6. Participants in other clinical trials within the last two months 7. Patients with severe arrhythmia or cardiac dysfunction(EF\<40%) 8. There was a clear history of neurological and psychiatric problems or long-term use of sedatives or antidepressants 9. History of cerebrovascular disease or brain surgery or trauma 10. Severe liver dysfunction (Child-Pugh class C) or severe renal dysfunction (requiring dialysis)
Conditions2
DiabetesPostoperative Delirium
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorXie Kangjie
Started2024-05-20
Est. completion2025-12-30
Eligibility
Age65 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06426953